Resources to Advance Pediatrics and HIV Prevention Science: Scientific and Quality/Regulatory Support Services

推进儿科和艾滋病毒预防科学的资源：科学和质量/监管支持服务

• 批准号: 10927010
• 负责人: PETER SILVERA
• 金额: $ 6.11万
• 依托单位: ADVANCED BIOSCIENCE LABORATORIES, INC.
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-07-15 至 2024-07-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10927010
• 关键词: AIDS prevention; Biological; Biological Assay; Cells; Collaborations; Communities; Contraceptive Agents; Contractor; Contracts; Development; Devices; Equipment and supply inventories; Extramural Activities; Formulation; HIV; Investigator-Initiated Research; Liquid substance; National Institute of Allergy and Infectious Disease; Pediatrics; Prevention; Private Sector; Reagent; Research; Resources; SIV; Science; Services; Shipping; Specimen; Tissues; archive data; co-infection; data archive; novel therapeutics; pathogen; pre-clinical; product development; research clinical testing; research study; therapeutic development

The objective of the Resource to Advance Pediatrics and HIV Prevention Science contracts is to provide the extramural scientific community with research materials and preclinical product development support for candidate products that emerge from investigator-initiated research studies, or from collaborations with private sector or academic partners. These services may also be used to support product discovery and development leading to IND, Investigational Device Exemption (IDE), and/or New Drug Application (NDA) filings with the FDA. NIAID will primarily use these contracts to fill critical development and resource gaps more rapidly and efficiently and advance promising products into clinical testing. The focus of these contracts will be development of therapeutics and prevention products for HIV, including single or combination products with activity against associated co-infections or MPTs that incorporate contraceptives.

该资源的目的是促进儿科和艾滋病毒预防科学合同是提供研究材料和临床前产品开发支持的候选产品，出现从制药商发起的研究，或从与私营部门或学术合作伙伴的合作校外科学界。这些服务还可用于支持产品发现和开发，从而向FDA提交IND、试验用器械豁免（IDE）和/或新药申请（NDA）。NIAID将主要利用这些合同更快、更有效地填补关键的开发和资源缺口，并将有前途的产品推进临床测试。这些合同的重点将是开发艾滋病毒的治疗和预防产品，包括具有抗相关合并感染或含有避孕药的MPT活性的单一或组合产品。